The appointment signals board strengthening with a capital markets-savvy executive, potentially positioning for future financings or strategic moves. Monitor for increased engagement from RA Capital or similar investors given Dable's ties.
Price Chart
Executive Summary
Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effective April 16, 2026. Dable, a seasoned biopharma executive and current advisor at RA Capital, was granted stock options to purchase 44,400 shares. The move expands the board from nine to ten members.
Key Facts
- Habib J. Dable appointed to the board of directors effective April 16, 2026
- Board size increased from nine to ten members
- Dable is a former CEO of Acceleron Pharma and holds board roles at multiple biotech firms
- Granted options to purchase 44,400 shares of common stock, vesting over 36 months
- Board determined Dable is independent under Nasdaq rules
Financial Impact
Approximately $1.1 million in initial equity grant (based on 44,400 options at $24.70/share, TYRA's implied price at time of grant)
Risk Factors
- Limited immediate operational impact from director appointment
- Equity grant contributes to share dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-160347 |
| Document: 0001193125-26-160347-index-headers.html | 0001193125-26-160347 |
| Document: 0001193125-26-160347-index.html | 0001193125-26-160347 |
| Document: 0001193125-26-160347.txt | 0001193125-26-160347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | S-3ASR | $25.07 $25.65 | ▲ +2.31% | ▲ +2.21% | $20.50 (−18.21%) |
Sep 9, 2026 23d ago | 8-K | $22.01 $24.35 | ▲ +10.63% | ▲ +11.73% | $20.50 (−6.84%) |
Aug 4, 2026 8w ago | 424B5 | $25.71 $25.30 | ▲ +1.59% | ▲ +1.95% | $20.50 (+20.25%) |
Jun 26, 2026 13w ago | 144 | $32.11 $30.86 | ▲ +3.89% | ▲ +5.28% | $20.50 (+36.14%) |
May 13, 2026 20w ago | 8-K | $36.19 $33.78 | ▼ −6.66% | ▼ −5.50% | $20.50 (−43.34%) |
Apr 20, 2026 23w ago | 3 | $36.69 $35.06 | ▼ −4.44% | ▼ −5.53% | $20.50 (−44.11%) |
Apr 17, 2026 24w ago | DEFA14A | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 17, 2026 24w ago | 8-K | $35.56 $37.59 | ▲ +5.71% | ▲ +5.15% | $20.50 (−42.34%) |
Apr 13, 2026 24w ago | 144 | $35.27 $36.69 | ▲ +4.03% | ▲ +2.63% | $20.50 (−41.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access